22.11.2023, Author: Juliane Zielonka

Stock news: Gloomy outlook for Bayer AG - Historic low after study failure and billion-euro lawsuit — Pharmaceuticals and Agriculture divisions suffer severe setbacks

  • Bayer
  • Pharma
  • Glyphosat
  • Agrar
  • Consumer Health
  • Healthcare

Bayer's economic future is currently on shaky ground. The shares of the Group with its three pillars, Consumer Health, Pharma, and Agriculture, fell by almost 20% this week after a late-stage drug trial in the Pharma division was halted. In addition, a considerable compensation payment of EUR 1.5 billion in connection with the US glyphosate business has put the Leverkusen-based company in an unusually precarious position. The Company lost around EUR 7.7 billion in value in one day due to the price slide, and the share price fell to EUR 33, marking a historic low for Bayer AG shares since the financial crisis in 2009. Currently, the Bayer Group is only worth around EUR 32.77 billion. What needs to happen now for a possible way out of this dilemma? Would the often talked-about split-up of the Group be a solution for the further growth of the Group?

Time to read: 6 minutes

Pharmaceuticals division: The EUR 4.5 billion dream of Xarelto successor has been dashed in late-stage study

High hopes were pinned on 'Asundexian', Bayer's anticoagulant for patients with atrial fibrillation who have an increased risk of stroke. The drug was expected to generate annual sales of more than EUR 4.5 billion. It was specifically intended to replace the future loss of revenue from the anticoagulant 'Xarelto', whose European patent protection expires in 2026.

Last year, the hopeful drug failed to beat the placebo in two mid-sized trials involving patients after heart attacks and a specific type of stroke.1 . Now, the molecule has also failed in a Phase III trial. The Bayer team will analyze the data to understand why 'Asundexian' fell short of expectations.

"Although the results of this analysis do not support the continuation of the OCEANIC-AF trial, we will continue to investigate Asundexian in the OCEANIC-STROKE trial and are currently re-evaluating other indications in patients requiring antithrombotic treatment" said Dr. Christian Rommel, Member of the Board of Management of the Pharmaceuticals Division of Bayer AG and Global Head of Research and Development. 2 . After all, the hoped-for EUR 4.5 billion represents 10% of the forecasts made by CEO Bill Anderson for the entire financial year when he took office. 3 . Now, they have failed to materialize.

CEO Bill Anderson will cut back on the Group's management levels. "There are still 12 layers between me and our customers. That's just too much." Source: Bayer AG

Agriculture division: US jury rejects glyphosate damages claim worth USD 1.56 billion

The good news for investors: The European Union will extend the approval of glyphosate by 10 years, even though its member states could not agree on the same active ingredient in Bayer AG's weedkiller 'Roundup'. This is based on safety assessments by the European Food Safety Authority and the European Chemicals Agency. However, new conditions and restrictions apply, including maximum use rates.

Food for thought: Glyphosate has been controversial since the WHO's cancer research agency concluded in 2015 that it was presumably carcinogenic to humans. Other agencies worldwide, including the US Environmental Protection Agency (EPA) and EU agencies, have classified it as non-carcinogenic.

These conclusions now face a brand new claim for damages of USD 1.56 billion from the US. The intriguing detail about the recent ruling is that this time, cancer is also listed as an injury. On November 19, 2023, according to Reuters 4 , a Missouri jury ordered Bayer to pay USD 1.56 billion (EUR 1.42 billion) to four plaintiffs alleging that Bayer's Roundup™ weedkiller caused injuries, including cancer.

The verdict could increase pressure on the German company to change its legal strategy. According to recent court documents, the US jury ruled that Bayer's Monsanto division was liable for negligence, design defect, and negligence by omission because the plaintiffs were not adequately warned of the potential dangers of using 'Roundup™'.

Plaintiffs Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California were awarded a combined USD 61.1 million in compensatory damages and USD 500 million each in punitive damages. All three were diagnosed with non-Hodgkin's lymphoma, which they attributed to the use of Roundup on their family property. Draeger's wife, Brenda, was awarded USD 100,000 for the alleged damages caused by her husband's illness. The fact that cases of cancer from handling the herbicide are increasing should at least give investors pause for thought.

Finances - Goodwill becomes a risk

In addition to the developments in the pharmaceutical business, Bayer is facing an additional challenge: goodwill. Goodwill of around EUR 39 billion was reported in the 2022 annual balance sheet. In July, the Company announced that it had to write off EUR 2.5 billion due to problems in the glyphosate business, resulting in a loss of EUR 2 billion in the second quarter. The quarterly figures from Q3/23 currently show goodwill of around EUR 33.87 billion compared to equity of EUR 33.56 billion 5

Goodwill 6 is used to more accurately represent the overall value of a company, especially when intangible assets play a significant role. It can be helpful in assessing a company's financial health and market position. Goodwill is calculated by taking the purchase price of a company and subtracting the difference between the estimated value of assets and liabilities. Companies must review the goodwill value in their financial reports at least once a year and record any impairment losses.

For this financial year, Bayer's high goodwill compared to equity remains a critical issue. In addition, the Company is now worth less on the stock market than its net debt. The net debt stands at EUR 38.1 billion compared to the EUR 32.77 billion market capitalization.

Interim conclusion:

CEO Bill Anderson needs more compelling arguments to show investors that a restructuring might be necessary. Separating the agriculture business is risky due to ongoing legal risks and the numerous claims for damages and lawsuits. Spinning off Pharma is no less risky with the failure of the Phase III trial. Therefore, Bayer's latest share price loss could mean the Company's various divisions remain together. As Anderson announced in the last quarterly results, the cost-cutting measures will be implemented at the organizational level.

The performance of Bayer AG over the last year compared to peers, GSK, and the DAX. Clearly visible: the slide in the Leverkusen share price. An end is not yet in sight. Source: Refinitiv - Retrieved November 21, 2023
Bill Anderson, CEO

"*In terms of this year's performance, we are not satisfied. Almost EUR 50 billion in sales but no positive cash flow is simply not acceptable*."

By the end of 2024, Bayer plans to significantly reduce its workforce by eliminating several layers of management. Anderson emphasizes that these will not be traditional cost-cutting layoffs. Instead, the role of small, self-managed teams that operate closer to customers and patients will be strengthened. "There are still 12 layers between me and our customers. That's just too much." If Anderson now draws the invisible sword of employer branding to force a cultural change, investors can expect change management to take 3 to 5 years until sustainable changes take effect. This is the typical duration for organizational transformation. 7 . However, investors might find solace in CEO Anderson's experience, as he successfully executed a similar transformation in his previous position with Roche. The result was a shift from an inflated bureaucratic structure to a more entrepreneurial organization. 8 .

The update is based on the initial report 04/2022.


Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

For this reason, there is a concrete conflict of interest.

The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

Source: Bayer AG

Media comments

Juliane Zielonka

Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

More about the author

Further analyses